An FDA panel endorsed the approval of Janssen's simeprevir to be used in combination with peginterferon alfa and ribavirin to treat chronic hepatitis C in treatment-naive adults with compensated liver disease. The therapy is also intended for patients who did not respond to previous interferon treatment.
Janssen's hepatitis C drug gets FDA panel endorsement
SmartBrief Job Listings for Health Care
|Sr. Business Systems Analyst||
|Chief Operating Officer||
Presence Health Partners
|Des Plaines, IL|
|Leadership Recruiting Manager||
|Sr. Reimbursement Analyst||
Olympus America Inc.
|Sr. Report Developer Medical Claims||
Geisinger Health System